Clinical Trial Finder

Inclusion Criteria:

1. Is willing and able to provide written informed consent for the trial. 2. Is ≥18 years of age on the day of signing informed consent. 3. Has a histologically confirmed advanced malignancy. Subjects with CTCL [MF or SS] who satisfy the Phase 2a, Cohort 3-specific eligibility criteria may be enrolled into the Phase 1 part of the study. 4. Is intolerant of, refuses, or is not eligible for standard antineoplastic therapy. 5. Has at least 1 measurable disease lesion as defined by RECIST. 6. Is able to safely undergo a baseline tumor tissue biopsy prior to first dose of BI-1808 (on non previously irradiated lesions only). The biopsy must be performed at least 4 weeks following the last dose of tumor directed therapy. 7. Has a life expectancy of ≥12 weeks. 8. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 9. Has adequate organ function as confirmed by laboratory values. Phase 2a Expansion Cohort-Specific

Inclusion Criteria:

Ovarian Cancer: Histologically confirmed and documented recurrent ovarian, fallopian tube, and peritoneal cancer. TCL: 1. histologically confirmed diagnosis. 2. Stable doses of systemic steroids (≤20 mg prednisone equivalent) and of low-to-medium potency topical steroids permitted (no change in preceding 4 weeks). 3. Stage IB-IV with failure of at least 1 systemic therapy. 4. No current large cell transformation for subjects with CTCL. 5. Prior therapy

• - No prior allo hematopoietic stem cell transplantation (HSCT); >90 days since auto HSCT; >4 weeks since systemic therapy and >2 weeks since skin-directed therapy.

6. Stable doses of systemic steroids (≤20 mg prednisone equivalent) and of low-to-medium potency topical steroids permitted (no change in preceding 4 weeks). 7. Previous systemic therapies include brentuximab vedotin, bexarotene, extracorporeal photopheresis (ECP), methotrexate, mogamulizumab, romidepsin, vorinostat, or systemic therapy with localized radiation treatment or skin-directed therapy. Melanoma: 1. Histologically confirmed diagnosis of unresectable or metastatic melanoma. Subjects in Part A: 2. Required prior therapies will include anti-programmed death-ligand 1 (PD-1) therapy either as monotherapy or as part of a combination regimen. 3. For subjects with a known BRAF V600-activating mutation combination targeted therapy will be required in addition to anti-PD-1/programmed death-ligand 1 (PD-L1) therapy. Subjects in part B: 4. Subjects with prior lines of treatment are not eligible. All Tumor Types: Locally advanced unresectable, recurrent or metastatic immune checkpoint inhibitor-naïve solid tumors, likely to benefit from immune checkpoint inhibitor treatment, based on Investigator opinion. b. Subjects must have received prior standard therapy appropriate for their tumor type and stage of disease, or in the opinion of the Investigator, would be unlikely to tolerate or derive clinical benefit from appropriate standard of care therapy. c. Subjects with known activation mutations must have prior target therapy.

Exclusion Criteria:

1. Needs doses of prednisolone >10 mg daily (or equipotent doses of other corticosteroids) while on the trial other than as premedication. 2. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. 3. Has known or suspected hypersensitivity to BI-1808 or pembrolizumab. 4. Has cardiac or renal amyloid light-chain amyloidosis. 5. Has received the following: 1. Chemotherapy or small molecule products within 4 weeks of first dose of BI-1808. 2. Radiotherapy within 2 weeks of first dose of BI-1808. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) for non-CNS disease. Subjects who have previously had radiation pneumonitis are not allowed. 3. Immunotherapy within 4 weeks prior to the first dose of BI-1808. 6. Has not recovered from AEs to at least Grade 1 by NCI CTCAE. 7. Has had Grade ≥3 autoimmune manifestations of previous immune checkpoint inhibitor treatments (eg, anti-PD-1, anti-PD-L1, or anti-CTLA-4). 8. Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis. 9. Has an active, known, or suspected autoimmune disease. 10. Is a female subject and has the ability to become pregnant (or already pregnant or lactating/breastfeeding). However, those female subjects who have a negative serum or urine pregnancy test before enrollment and agree to use a highly effective method of birth control for 4 weeks before entering the trial, during the trial, and for 12 months after last dose of BI-1808, are considered eligible. 11. Is a male subject with partner(s) of childbearing potential (unless he agrees to take measures not to father children by using 1 form of highly effective contraception [condom plus spermicide gel] during the trial and for 12 months after completing treatment). 12. Has had major surgery from which the subject has not yet recovered. 13. Is at high medical risk because of nonmalignant systemic disease including severe active infections on treatment with antibiotics, antifungals, or antivirals. 14. Has presence of chronic graft versus host disease. 15. Has had an allogenic tissue/solid organ transplant. 16. Has known human immunodeficiency (HIV) and/or history of hepatitis B or C infections, or has a positive test for HIV antibody, hepatitis B antigen/hepatitis B virus DNA or hepatitis C antibody or RNA. 17. Has a history of active tuberculosis (Bacillus tuberculosis). 18. Has received a live vaccine within 30 days before the first dose of study treatment. 19. Has uncontrolled or significant cardiovascular disease. 20. Has a known psychiatric or substance abuse disorder that would interfere with the subject's ability to cooperate with the requirements of the trial. 21. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator. 22. Is participating or planning to participate in another interventional clinical trial, or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to first dose of study drug. 23. Has a known additional malignancy of another type, with the exception of adequately treated cone biopsied carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) and basal or squamous cell carcinoma of the skin. Male subjects with asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for >1 year prior to start of trial therapy are eligible. 24. Has a diagnosis of primary or acquired immunodeficiency disorder or taking any other form of immunosuppressive therapy within 7 days prior the first dose of study drug. 25. Has symptomatic ascites or pleural effusion, requires surgical intervention of additional medication

This is a Phase 1/2a, dose-escalation, multicenter, first-in-human, consecutive-cohort, open-label study of BI-1808, as a single agent and in combination with pembrolizumab in subjects with advanced malignancies, whose disease has progressed after standard therapy. The study will consist of 2 phases: a Phase 1 with Parts A and B, and a Phase 2a with Parts A and B. Phase 1 Part A consists of a dose escalation of BI-1808 as a single agent to evaluate safety and tolerability and to determine the RP2D as a single agent (sRP2D) in subjects with advanced malignancies whose disease has progressed after standard therapy. Phase 1 Part B consists of a dose escalation of BI-1808 in combination with pembrolizumab to evaluate the safety and tolerability of the combination treatment and to allow selection of the RP2D for BI-1808 in combination with pembrolizumab (cRP2D) in subjects with advanced malignancies whose disease has progressed after standard therapy. Phase 2a will assess BI-1808 administered as a single agent (Part A) and in combination with pembrolizumab (Part B) at the respective hypothesized RP2D(s) determined in Phase 1. Phase 2a expansion will be conducted in indication specific cohorts of subjects. The aim of the Phase 2a is to further assess the safety and tolerability of BI-1808 as a single agent (Part A) and in combination with pembrolizumab (Part B), characterize its PK and pharmacodynamics, and assess preliminary antitumor activity by ORR, DoR, and progression-free survival (PFS), as measured by RECIST v1.1 and iRECIST.

Arms

Experimental: Phase I, Part A - Dose escalation and safety of BI-1808 as single agent

Dose escalation of BI-1808 administrated a single agent

Experimental: Phase I, Part B - Dose escalation and Safety of BI-1808 in combination with pembrolizumab

Dose escalation of BI-1808 in combination with pembrolizumab.

Experimental: Phase 2a - Part A dose expansion of BI-1808 as a single agent

BI-1808 administered as a single agent at the hypothesized recommended phase 2 dose determined in Phase 1

Experimental: Phase 2a, Part B - Dose expansion of BI-1808 in combination with pembrolizumab

BI-1808 administered in combination with pembrolizumab at the respective hypothesized recommended phase 2 doses determined in Phase 1

Interventions

Drug: - BI-1808

BI-1808 administered as a flat-dose IV infusion once every 3 weeks

Drug: - Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection

Pembrolizumab administered as a flat-dose IV infusion once every 3 weeks.